COMMUNIQUÉ DE PRESSE publié le 16/04/2024 à 14:30, il y a 5 mois 4 jours Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care Jaguar Health, Inc. announces commercial launch in Q3 2024 for Gelclair® for cancer supportive care. Gelclair is an FDA-approved oral mucositis prescription product for pain management in oncology Jaguar Health Inc. Commercial Launch Gelclair Oral Mucositis Prescription Product
BRÈVE publiée le 09/04/2024 à 22:20, il y a 5 mois 10 jours Jaguar Health annonce une assemblée d’actionnaires réussie et des progrès dans les essais cliniques Assemblée Générale Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai Clinique Crofelemer
BRÈVE publiée le 09/04/2024 à 22:20, il y a 5 mois 10 jours Jaguar Health Reports Successful Stockholder Meeting and Progress on Clinical Trial Jaguar Health Nasdaq Compliance Cancer Therapy Stockholder Meeting Crofelemer Clinical Trial
COMMUNIQUÉ DE PRESSE publié le 09/04/2024 à 22:15, il y a 5 mois 10 jours Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders Jaguar Health, Inc. announces decision not to implement a reverse split at this time. Top line results for phase 3 OnTarget trial of crofelemer pending. Stockholders approve proposals at Special Meeting Crofelemer Stockholders Meeting Jaguar Health Reverse Split Phase 3 Trial
BRÈVE publiée le 08/04/2024 à 14:35, il y a 5 mois 12 jours Jaguar Health Granted Extension to Regain Nasdaq Compliance, Announces OnTarget Trial Results Soon Crofelemer Jaguar Health Nasdaq Compliance Cancer Therapy OnTarget Trial
BRÈVE publiée le 08/04/2024 à 14:35, il y a 5 mois 12 jours Jaguar Health obtient une prolongation pour rétablir la conformité au Nasdaq et annonce bientôt les résultats de l'essai OnTarget Crofelemer Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai OnTarget
COMMUNIQUÉ DE PRESSE publié le 08/04/2024 à 14:30, il y a 5 mois 12 jours Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement Jaguar Health, Inc. announces extended grace period from Nasdaq for bid price compliance. Top line results awaited for crofelemer's cancer therapy-related diarrhea prevention trial Crofelemer Nasdaq Jaguar Health Cancer Therapy Grace Period
BRÈVE publiée le 02/04/2024 à 14:35, il y a 5 mois 18 jours Jaguar Health, Inc. annonce la nomination d'un vétéran de l'industrie pharmaceutique européenne au poste de président de Jaguar International Crofelemer Expansion Commerciale Industrie Pharmaceutique Santé Jaguar Massimo Radaelli
BRÈVE publiée le 02/04/2024 à 14:35, il y a 5 mois 18 jours Jaguar Health, Inc. Announces Appointment of European Pharmaceutical Industry Veteran as President of Jaguar International Pharmaceutical Industry Crofelemer Jaguar Health Massimo Radaelli Commercial Expansion
COMMUNIQUÉ DE PRESSE publié le 02/04/2024 à 14:30, il y a 5 mois 18 jours Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International Dr. Massimo Radaelli appointed as President of Jaguar International to expand commercial footprint globally with recent out-license agreement. Key pharmaceutical industry leader with vast experience and expertise Pharmaceutical Industry Jaguar Health International Expansion Massimo Radaelli Out-license Agreement
Publié le 20/09/2024 à 17:40, il y a 1 heure 56 minutes Availability of the 2024 Half-Year Financial Report
Publié le 20/09/2024 à 17:40, il y a 1 heure 56 minutes Mise à disposition du Rapport Financier Semestriel 2024
Publié le 20/09/2024 à 19:00, il y a 36 minutes EquityMultiple Anticipates Key Opportunities Following Federal Rate Cuts
Publié le 20/09/2024 à 15:00, il y a 4 heures 36 minutes DISCOVER FH Collaboration With Family Heart Foundation, UT Southwestern, and Partners
Publié le 20/09/2024 à 15:00, il y a 4 heures 36 minutes Tacora Resources Inc. completes CCAA Sale Transaction, Emerging with a Strengthened Balance Sheet, Renewed Conviction on High-Grade Iron Ore, and a Plan to Realize Production Growth
Publié le 20/09/2024 à 14:30, il y a 5 heures 6 minutes Focus Universal Inc. Announces Listing Transfer to Nasdaq Capital Market
Publié le 20/09/2024 à 18:51, il y a 45 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 20/09/2024 à 15:29, il y a 4 heures 6 minutes Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
Publié le 20/09/2024 à 15:14, il y a 4 heures 22 minutes a sknet becomes part of Academic Software Resulting in a powerful combination of two leaders in digital education.
Publié le 20/09/2024 à 14:59, il y a 4 heures 37 minutes Form 8.3 - The Vanguard Group, Inc.: Darktrace plc